Brentuximab Vedotin



Indications and Reactions:

Role Indications Reactions
Primary
Hodgkin's Disease 61.7%
Hodgkin's Lymphoma 9.7%
Hodgkin's Disease Refractory 5.7%
Product Used For Unknown Indication 3.7%
Hodgkin's Disease Recurrent 3.0%
Diffuse Large B-cell Lymphoma 2.7%
Lymphoma 2.3%
Acute Graft Versus Host Disease 2.0%
Anaplastic Large-cell Lymphoma 1.3%
Non-hodgkin's Lymphoma 1.3%
T-cell Lymphoma 1.3%
Angioimmunoblastic T-cell Lymphoma 1.0%
Mycosis Fungoides 1.0%
Drug Use For Unknown Indication 0.7%
Hodgkin's Disease Stage Iv 0.7%
Hodgkin's Lymphoma 0.3%
Acute Myeloid Leukaemia 0.3%
Anaplastic Large Cell Lymphoma T- And Null-cell Types 0.3%
Germ Cell Cancer 0.3%
Lymphomatoid Papulosis 0.3%
Vomiting 14.1%
Febrile Neutropenia 9.4%
Pyrexia 9.4%
Sepsis 9.4%
White Blood Cell Count Decreased 8.2%
Pancreatitis 7.1%
Pneumonia 5.9%
Death 3.5%
Stem Cell Transplant 3.5%
Thrombocytopenia 3.5%
Urticaria 3.5%
Weight Decreased 3.5%
Gastrointestinal Infection 2.4%
Neutropenia 2.4%
Oral Candidiasis 2.4%
Pancytopenia 2.4%
Platelet Count Decreased 2.4%
Rash 2.4%
Rash Maculo-papular 2.4%
Sinus Tachycardia 2.4%
Secondary
Hodgkin's Disease 43.1%
Anaplastic Large-cell Lymphoma 13.9%
Product Used For Unknown Indication 11.1%
Anaplastic Large Cell Lymphoma T- And Null-cell Types 8.3%
T-cell Prolymphocytic Leukaemia 8.3%
Prophylaxis Against Graft Versus Host Disease 4.2%
Chemotherapy 2.8%
Lymphoma 2.8%
Vasculitis Necrotising 2.8%
Mycosis Fungoides Refractory 1.4%
T-cell Lymphoma Recurrent 1.4%
Diabetes Mellitus 7.7%
Infusion Related Reaction 7.7%
Oedema 7.7%
Pneumonia 7.7%
Pulmonary Toxicity 7.7%
Pyrexia 7.7%
Respiratory Failure 7.7%
Therapeutic Product Ineffective 7.7%
Thrombocytopenia 7.7%
Transplant Rejection 7.7%
Vasculitis Necrotising 7.7%
Vomiting 7.7%
Weight Decreased 7.7%
Concomitant
Anaplastic Large Cell Lymphoma T- And Null-cell Types 51.2%
Mycosis Fungoides 46.5%
Chronic Lymphocytic Leukaemia Refractory 2.3%
Sepsis 66.7%
Vomiting 33.3%
Interacting
Product Used For Unknown Indication 51.1%
Hiv Infection 12.8%
Antiemetic Supportive Care 6.4%
Hodgkin's Disease 6.4%
Prophylaxis 6.4%
Blood Glucose Increased 4.3%
Enzyme Inhibition 4.3%
Haematological Malignancy 4.3%
Antibiotic Prophylaxis 2.1%
Gastrointestinal Disorder 2.1%
Vomiting 50.0%
Drug Interaction 25.0%
Sepsis 25.0%